Understanding how IGFBP3 affects resistance to Olaparib in advanced prostate cancer
Official title: Novel roles of IGFBP3 in Olaparib resistance in advanced prostate cancer
Funded at VA Northern California Health Care Sys · NIH-11034085 · Data updated 2026-11-12
This study is looking at how a protein called IGFBP3 affects advanced prostate cancer's ability to resist a treatment called Olaparib, with the goal of finding better ways to help patients respond to this therapy.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | VA Northern California Health Care Sys NIH-funded |
| Lab location | 1 site (Mather, United States) |
| Project start | March 1, 2024 |
| Project end | February 29, 2028 |
| Funding year | 2025 |
| NIH project number | 5I01BX006198-02 |
| Project ID | NIH-11034085 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with advanced prostate cancer who have shown resistance to Olaparib or similar PARP inhibitors.
✕Less likely to help
Patients with early-stage prostate cancer or those who have not been treated with Olaparib may not benefit from this research.
What this research studies
This research investigates the role of IGFBP3 in the resistance of advanced prostate cancer to a treatment called Olaparib, which targets cancer cells with DNA damage repair defects. The study uses advanced cell lines that have developed resistance to Olaparib to explore how IGFBP3 influences cancer cell survival and response to treatment. By analyzing changes in gene expression and cellular behavior, the research aims to identify potential new strategies to overcome resistance and improve treatment outcomes for patients.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with advanced prostate cancer who are resistant to current therapies.
How similar studies have gone: Other research has shown promising results in targeting resistance mechanisms in cancer therapies, suggesting that this approach could yield significant insights.
Where this research is happening
-
VA Northern California Health Care Sys
Mather, United States Active
Researchers
- Principal investigator: Gao, Allen C. — VA Northern California Health Care Sys
- Study coordinator: Gao, Allen C.
Related research
Other NIH-funded projects on the same topics.
-
Drug that blocks tumor-made male hormones and the androgen receptor for advanced prostate cancer
A new medicine aims to block both the androgen receptor and the tumor’s own production of male hormones to help men with advanced, treatment‑resistant prostate cancer.
-
Boosting a tumor-suppressing enzyme to fight advanced prostate cancer
A research grant aims to develop new molecules that enhance the PP2A enzyme to slow or stop progression of advanced prostate cancer.
-
Modulating Androgen Signals to Boost CAR T Therapy for Prostate Cancer
A new approach uses CAR T cells targeting STEAP1 to treat advanced prostate cancer, with a focus on how androgen signals affect treatment effectiveness.
-
Genomic clues to guide therapy in advanced prostate cancer
This grant looks at how a patient’s tumor and germline DNA could predict which targeted or immune therapies will work best for advanced prostate cancer.
-
DACH1-based test to predict therapy response in advanced prostate cancer
A new test using DACH1 and other markers on prostate cancer tissue aims to predict which patients will respond to therapy and guide clinical trials.
-
Understanding how doctors choose treatments to improve advanced prostate cancer care
A clinician-researcher at Duke is exploring how medical decisions are made in advanced prostate cancer to help patients get better, fairer care.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.